盟科药业：与蓬勃生物达成战略合作 联合开发ADC药物

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Nanjing Pengbo Biotechnology Co., Ltd. to jointly develop innovative antibody-drug conjugates (ADCs) leveraging their respective platforms [2][3] Group 1: Company Overview - Mengke Pharmaceutical focuses on the design and development of small molecule new drugs, aiming to discover, develop, and commercialize innovative drugs that meet unmet clinical needs [2] - The company has successfully developed a new STOPIN (Soft Topoisomerase Inhibitor) platform to address dose-limiting toxicities caused by toxins in next-generation ADC development [2] Group 2: Research and Development Progress - Mengke Pharmaceutical presented research progress on a new ADC product based on the STOPIN toxin platform at the 2024 European Society for Medical Oncology (ESMO), showing excellent anti-tumor efficacy and lower hematological toxicity in animal trials [2] Group 3: Strategic Partnership - The partnership with Pengbo Biotechnology aims to maximize the applicability and competitiveness of the STOPIN platform technology, facilitating the development of competitive ADC drugs globally [3] - Pengbo Biotechnology provides comprehensive CDMO services to accelerate new drug development for biotech and pharmaceutical companies, covering clinical trials to commercial production [3]